<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2017-16-3-48-54</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Dynamics of the stabilometric parameters in children with the opsoclonus myoclonus syndrome in carrying out various rehabilitation methods</article-title><trans-title-group xml:lang="ru"><trans-title>Динамика изменений стабилометрических параметров у детей с синдромом опсоклонус-миоклонус при проведении различных реабилитационных методик</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0340-1670</contrib-id><name-alternatives><name xml:lang="en"><surname>Polyakov</surname><given-names>O. A.</given-names></name><name xml:lang="ru"><surname>Поляков</surname><given-names>О. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>M.D., postgraduate of the department of medical rehabilitation</p><p>Russia, 119571, Moscow, Leninskii prospect, 117 Tel.: +7 (495) 936-9041</p></bio><bio xml:lang="ru"><p>аспирант отделения медицинской реабилитации</p><p>119571, Москва, Ленинский пр-т, 117. Тел.: +7 (495) 936-9041</p></bio><email>poliak8989@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8084-1277</contrib-id><name-alternatives><name xml:lang="en"><surname>Laisheva</surname><given-names>O. A.</given-names></name><name xml:lang="ru"><surname>Лайшева</surname><given-names>О. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>no-reply@eco-vector.com</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5496-605X</contrib-id><name-alternatives><name xml:lang="en"><surname>Ilina</surname><given-names>E. S.</given-names></name><name xml:lang="ru"><surname>Ильина</surname><given-names>Е. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>no-reply@eco-vector.com</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9648-2336</contrib-id><name-alternatives><name xml:lang="en"><surname>Polyaev</surname><given-names>B. A.</given-names></name><name xml:lang="ru"><surname>Поляев</surname><given-names>Б. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>no-reply@eco-vector.com</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2281-9936</contrib-id><name-alternatives><name xml:lang="en"><surname>Parastaev</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Парастаев</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>no-reply@eco-vector.com</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Children's Clinical Hospital of the Ministry of Health of Russia&#13;
&#13;
Pirogov Russian National Research Medical University» of the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="ru">ФГБУ «Российская детская клиническая больница» Минздрава России, Москва</institution></aff><aff><institution xml:lang="en">Russian Children's Clinical Hospital of the Ministry of Health of Russia

Pirogov Russian National Research Medical University» of the Ministry of Health of Russia</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="ru">ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва</institution></aff><aff><institution xml:lang="en">Russian Children's Clinical Hospital of the Ministry of Health of Russia</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="ru">ФГБУ «Российская детская клиническая больница» Минздрава России, Москва</institution></aff><aff><institution xml:lang="en">Pirogov Russian National Research Medical University» of the Ministry of Health of Russia</institution></aff></aff-alternatives><aff id="aff5"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, Москва</institution></aff><pub-date date-type="pub" iso-8601-date="2017-08-10" publication-format="electronic"><day>10</day><month>08</month><year>2017</year></pub-date><volume>16</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>48</fpage><lpage>54</lpage><history><date date-type="received" iso-8601-date="2018-08-10"><day>10</day><month>08</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/67">https://hemoncim.com/jour/article/view/67</self-uri><abstract xml:lang="en"><p>Optimization of the choice of rehabilitation methods in children with the oploskonus myoclonus syndrome on the basis of the analysis of stabilometric parameters. The study included 48 children of both sexes in the age range from 3 to 7 years with the diagnosis of «opsclonus-myoclonus syndrome». All patients were separated into 4 groups according to applied rehabilitation methods: in the first group (12 patients) patients received craniosacral therapy, in the II group - modified Vojta therapy (13 patients), in the third group patients underwented an isolated course of Galileo vibration therapy (10 patients), in the fourth group patients received modified Vojta therapy together with Galileo vibration therapy (13 patients). Patients underwented the course of craniosacral therapy demonstrated the increases rates of speed (V) in 1.48 times and statokinesiogram square in 1.94 times after fifth procedure as compared with data before. In the second group 1.32 times speed decrease (V) and 1.56 statokinesiogram square decrease (S) were marked. In the third group there were 1.73 times statokinesiogram square increase (S) and the displacement of pressure center midposition in frontal plane (X) to the left after implementation of 10 manipulation. In the fourth group 1.42 times speed decrease (V) and 2.7 times statokinesiogram square decrease (S) were marked after implementation of 10 manipulation, as well as displacement of pressure center midposition (X) in frontal plane to the right and tendency to displacement of pressure center in sagittal plane to the front after conducted manipulations. Modified Vojta therapy together with Galileo vibration therapy can be applied in the capacity of most effective rehabilitation methods for children with opsoclonus-myoclonus syndrome leading to useful increase of stabilometric parameteres.</p></abstract><trans-abstract xml:lang="ru"><p>Исследование проведено с целью оптимизации выбора реабилитационных методик у детей с синдромом опсоклонус-миоклонус на основании анализа стабилометрических параметров.</p> <p>Пациенты (48 детей обоего пола в возрасте от 3 до 7 лет) с диагнозом «опсоклонус-миоклонус синдром» были разделены на 4 группы в зависимости от применяемых реабилитационных методик: в I группе пациенты (12 человек) получали краниосакральную терапию; во II группе (13 человек) – модифицированную Войта-терапию; в III группе (10 человек) – изолированный курс вибрационной терапии на платформе Galileo; в IV группе (13 человек) – модифицированную Войта-терапию совместно с вибрационной терапией на платформе Galileo. Пациенты I группы демонстрировали увеличение скорости (V) в 1,48 раза и площади статокинезиограммы (S) в 1,94 раза после 5-й процедуры по сравнению с исходными данными. Во II группе после 10-й процедуры отмечено снижение показателей V и S – соответственно в 1,32 и 1,56 раза. В III группе после 10-й процедуры наблюдалось увеличение S в 1,73 раза и смещение среднего положения общего центра давления (ОЦД) во фронтальной плоскости влево. В IV группе после 10-й процедуры отмечены снижение показателей V и S – соответственно в 1,42 и 2,7 раза; смещение ОЦД (X) во фронтальной плоскости вправо, а также тенденция к смещению ОЦД (Y) в сагиттальной плоскости кпереди.</p> <p>Модифицированную Войта-терапию совместно с вибрационной терапией на тренажере Galileo можно применять как наиболее эффективную реабилитационную методику для детей с синдромом опсоклонус-миоклонус, приводящую к значимому улучшению стабилометрических показателей.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rehabilitation</kwd><kwd>opsoclonus-myoclonus syndrome</kwd><kwd>modified Vojta therapy</kwd><kwd>craniosacral therapy</kwd><kwd>Galileo vibration therapy</kwd><kwd>stabilometry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>реабилитация</kwd><kwd>синдром опсоклонус-миоклонус</kwd><kwd>модифицированная Войта-терапия</kwd><kwd>краниосакральная терапия</kwd><kwd>вибрационная терапия на платформе Galileo</kwd><kwd>стабилометрия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Gorman M.P. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Current opinion in pediatrics 2010; 22 (6): 745-50.</mixed-citation><mixed-citation xml:lang="ru">Gorman M.P. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Current opinion in pediatrics 2010; 22 (6): 745-50.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Pang K.K., et al. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus myoclonus syndrome in the United Kindom. Eur J Pediatr Neurol 2010; 14: 156-61.</mixed-citation><mixed-citation xml:lang="ru">Pang K.K., et al. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus myoclonus syndrome in the United Kindom. Eur J Pediatr Neurol 2010; 14: 156-61.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr 2009; 48: 336-40.</mixed-citation><mixed-citation xml:lang="ru">Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr 2009; 48: 336-40.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Pediatr Neurol 2010; 14: 400-9.</mixed-citation><mixed-citation xml:lang="ru">Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Pediatr Neurol 2010; 14: 400-9.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.</mixed-citation><mixed-citation xml:lang="ru">Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Pless M., Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996; 46 (2): 583-4.</mixed-citation><mixed-citation xml:lang="ru">Pless M., Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996; 46 (2): 583-4.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14 (5): 400-9.</mixed-citation><mixed-citation xml:lang="ru">Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14 (5): 400-9.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr (Phila) 2009; 48 (3): 336-40.</mixed-citation><mixed-citation xml:lang="ru">Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr (Phila) 2009; 48 (3): 336-40.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Rostásy K., et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatr 2006; 37 (5): 291-5.</mixed-citation><mixed-citation xml:lang="ru">Rostásy K., et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatr 2006; 37 (5): 291-5.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962; 25 (3): 271-6.</mixed-citation><mixed-citation xml:lang="ru">Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962; 25 (3): 271-6.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Boltshauser E., Deonna T., Hirt H.R. Myoclonic encephalopathy of infants or “dancing eyes syndrome”. Report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Pediatr Acta 1979; 34 (2): 119-33.</mixed-citation><mixed-citation xml:lang="ru">Boltshauser E., Deonna T., Hirt H.R. Myoclonic encephalopathy of infants or “dancing eyes syndrome”. Report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Pediatr Acta 1979; 34 (2): 119-33.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.</mixed-citation><mixed-citation xml:lang="ru">Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Krasenbrink I., et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatr 2007; 38 (3): 114-6.</mixed-citation><mixed-citation xml:lang="ru">Krasenbrink I., et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatr 2007; 38 (3): 114-6.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Pranzatelli M.R., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pedi-atr Hematol Oncol 2006; 28 (9): 585-93.</mixed-citation><mixed-citation xml:lang="ru">Pranzatelli M.R., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pedi-atr Hematol Oncol 2006; 28 (9): 585-93.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Pranzatelli M.R., et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24 (3): 316-22.</mixed-citation><mixed-citation xml:lang="ru">Pranzatelli M.R., et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24 (3): 316-22.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. de Grandis E., et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatr 2009; 40 (3): 103-11.</mixed-citation><mixed-citation xml:lang="ru">de Grandis E., et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatr 2009; 40 (3): 103-11.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Upledger J.E. Craniosacral therapy. Phys Ther 1995; 75 (4): 328-30.</mixed-citation><mixed-citation xml:lang="ru">Upledger J.E. Craniosacral therapy. Phys Ther 1995; 75 (4): 328-30.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
